Skip to main content

Table 1 Correlations between metformin use and clinic pathological characteristics in diabetic NSCLC patients (n = 255)

From: Prognostic value of metformin for non-small cell lung cancer patients with diabetes

  All (n = 255) Metformin (n = 150, 58.8%) Non-metformin (n = 105, 41.2%) p value
Age (years)
 ≥ 65 117 (45.9%) 63 (42.0%) 54 (51.4%) 0.565
 < 65 138 (54.1%) 87 (58.0%) 51 (48.6%)  
Gender (%)
 Male 204 (80.0%) 108 (72.0%) 96 (91.4%) 0.053
 Female 51 (20.0%) 42 (28.0%) 9 (8.6%)  
Smoking history
 No 21 (8.2%) 12 (8.0%) 9 (8.6%) 0.612
 Yes 234 (91.8%) 138 (92.0%) 96 (91.4%)  
BA1c (mmol/mol)   51.7 ± 14.5 53.3 ± 18.65 0.238
Histology
 Squamous 51 (20.0%) 24 (16.0%) 27 (15.7%) 0.357
 Non-squamous 204 (80.0%) 126 (84.0%) 78 (74.3%)  
Tumor location     0.189
 Left 114 (54.1%) 63 (42.0%) 51 (48.6%)  
 Right 141 (55.3%) 87 (58.0%) 54 (51.4%)  
Stage
 I 69 (27.1%) 42 (28.0%) 27 (25.7%) 0.541
 II 144 (56.5%) 87 (58.0%) 57 (54.3%)  
 III 42 (16.4%) 21 (14.0%) 21 (20.0%)  
Chemotherapy
 No 72 (28.2%) 45 (30.0%) 27 (25.7%) 0.200
 Yes 183 (72.8%) 105 (70.0%) 78 (75.3%)  
Thoracic irradiation
 No 213 (83.6%) 126 (84.0%) 87 (82.9%) 0.554
 Yes 42 (16.4%) 24 (16.0%) 18 (17.1%)  
Tumor recurrence
 No 165 (64.7%) 111 (74.0%) 54 (51.5%) 0.015
 Yes 90 (35.3%) 39 (26.0%) 51 (48.5%)